Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

BACKGROUND: Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with improved clinic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Ricciuti, Biagio, Kravets, Sasha, Dahlberg, Suzanne E., Umeton, Renato, Albayrak, Adem, Subegdjo, Safiya J., Johnson, Bruce E., Nishino, Mizuki, Sholl, Lynette M., Awad, Mark M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437848/
https://ncbi.nlm.nih.gov/pubmed/30922388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0572-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados